ZA200108254B - Combination preparation for treating malaria. - Google Patents

Combination preparation for treating malaria.

Info

Publication number
ZA200108254B
ZA200108254B ZA200108254A ZA200108254A ZA200108254B ZA 200108254 B ZA200108254 B ZA 200108254B ZA 200108254 A ZA200108254 A ZA 200108254A ZA 200108254 A ZA200108254 A ZA 200108254A ZA 200108254 B ZA200108254 B ZA 200108254B
Authority
ZA
South Africa
Prior art keywords
combination preparation
treating malaria
malaria
treating
proguanil
Prior art date
Application number
ZA200108254A
Other languages
English (en)
Inventor
Jeffrey David Chulay
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200108254B publication Critical patent/ZA200108254B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200108254A 1999-04-09 2001-10-08 Combination preparation for treating malaria. ZA200108254B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12867299P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
ZA200108254B true ZA200108254B (en) 2003-03-26

Family

ID=22436426

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108254A ZA200108254B (en) 1999-04-09 2001-10-08 Combination preparation for treating malaria.

Country Status (23)

Country Link
US (1) US6413993B1 (fr)
EP (1) EP1171108B1 (fr)
JP (1) JP2002541196A (fr)
KR (1) KR100613805B1 (fr)
CN (1) CN1152676C (fr)
AT (1) ATE241971T1 (fr)
AU (1) AU758167B2 (fr)
BR (1) BR0009676A (fr)
CA (1) CA2369089A1 (fr)
CZ (1) CZ294903B6 (fr)
DE (1) DE60003175T2 (fr)
DK (1) DK1171108T3 (fr)
ES (1) ES2199817T3 (fr)
HU (1) HUP0200842A3 (fr)
IL (2) IL145609A0 (fr)
MX (1) MXPA01010125A (fr)
NO (1) NO20014806L (fr)
NZ (1) NZ514353A (fr)
PL (1) PL350987A1 (fr)
PT (1) PT1171108E (fr)
TR (1) TR200102843T2 (fr)
WO (1) WO2000061133A1 (fr)
ZA (1) ZA200108254B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
CN102088956A (zh) * 2008-05-09 2011-06-08 托马有限公司 氯胍用于治疗皮肤/粘膜疾病
AU2009273747A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um
ES2517366T3 (es) * 2009-08-20 2014-11-03 Ipca Laboratories Limited Nuevo complejo para el tratamiento y/o profilaxis de infecciones parasitarias
EP3415147B1 (fr) * 2016-02-12 2025-04-02 Kao Corporation Inhibiteur de dégradation de mélanine
EP3522825B1 (fr) * 2016-10-05 2023-06-07 Titan Pharmaceuticals, Inc. Dispositifs implantables pour l'administration de médicaments caractérisés par une moindre libération massive et soudaine
WO2018204563A1 (fr) * 2017-05-03 2018-11-08 The Johns Hopkins University Atovaquone intramusculaire pour la prophylaxie du paludisme
CN107737108B (zh) * 2017-12-17 2018-06-26 姚蕾 一种治疗心肌梗死后心室重塑的口服药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) 1992-11-26 1993-01-13 Wellcome Found Medicaments
JPH0873355A (ja) * 1994-09-02 1996-03-19 Mitsui Toatsu Chem Inc 抗マラリア薬耐性克服剤

Also Published As

Publication number Publication date
DE60003175T2 (de) 2004-04-01
NZ514353A (en) 2003-10-31
MXPA01010125A (es) 2002-06-04
CA2369089A1 (fr) 2000-10-19
JP2002541196A (ja) 2002-12-03
TR200102843T2 (tr) 2002-01-21
KR20010108468A (ko) 2001-12-07
IL145609A (en) 2006-04-10
KR100613805B1 (ko) 2006-08-18
HK1041638A1 (en) 2002-07-19
NO20014806L (no) 2001-12-05
CN1346267A (zh) 2002-04-24
NO20014806D0 (no) 2001-10-03
PT1171108E (pt) 2003-10-31
ES2199817T3 (es) 2004-03-01
HUP0200842A3 (en) 2006-07-28
AU758167B2 (en) 2003-03-20
CZ20013646A3 (cs) 2002-06-12
CZ294903B6 (cs) 2005-04-13
US6413993B1 (en) 2002-07-02
AU4202200A (en) 2000-11-14
IL145609A0 (en) 2002-06-30
EP1171108A1 (fr) 2002-01-16
CN1152676C (zh) 2004-06-09
ATE241971T1 (de) 2003-06-15
BR0009676A (pt) 2002-09-03
EP1171108B1 (fr) 2003-06-04
DK1171108T3 (da) 2003-10-06
DE60003175D1 (de) 2003-07-10
WO2000061133A1 (fr) 2000-10-19
HUP0200842A2 (hu) 2002-07-29
PL350987A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
EP1634601A3 (fr) Complément alimentaire contenant du soja, champignon et fève de mung
GEP20053602B (en) Aripiprazole for Oral Administration
MY113059A (en) Controlled-release dosage forms of azithromycin
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
PT998287E (pt) Utilizacao de levobupivacaina
ZA200108254B (en) Combination preparation for treating malaria.
AU1167602A (en) Methods of therapy for hiv infection
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
GB0020504D0 (en) Therapeutic method
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2001076590A3 (fr) Traitement de la lombalgie benigne liee a la position
EP1143981A4 (fr) Traitement et prevention d'infections par le vih et d'autres infections virales
EP1347754A4 (fr) Compositions pour la prevention d'une adherence
AU2450900A (en) Therapeutic nucleoside compound
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
IL139064A0 (en) Intermittent claudication therapeutic drugs comprising pyrroloazepines
陈沛泉 et al. THE INFECTIVITY OF GAMETOCYTES OF PLASMODIUM FALCIPARUM FROM PATIENTS TREATED WITH ARTEMISININ
MD1469F1 (en) Method of treatment of the burn shock
EP1908477A3 (fr) Combinaison de témozolomide et interféron alpha pégylé pour le traitement du cancer
UA33715A (uk) Спосіб лікування залізодефіцитних анемій у вагітних
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
JO1462B1 (en) Mixture preparations for the treatment of malaria